1. Home
  2. FNWD vs BDTX Comparison

FNWD vs BDTX Comparison

Compare FNWD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

HOLD

Current Price

$43.26

Market Cap

147.7M

Sector

Finance

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$2.22

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWD
BDTX
Founded
1994
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
147.7M
171.9M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
FNWD
BDTX
Price
$43.26
$2.22
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$37.50
$9.67
AVG Volume (30 Days)
10.5K
573.6K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
1.51%
N/A
EPS Growth
N/A
130.71
EPS
1.00
N/A
Revenue
N/A
N/A
Revenue This Year
$17.40
N/A
Revenue Next Year
$5.44
N/A
P/E Ratio
$43.03
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.05
$1.60
52 Week High
$45.90
$4.94

Technical Indicators

Market Signals
Indicator
FNWD
BDTX
Relative Strength Index (RSI) 54.11 65.55
Support Level $36.08 $2.24
Resistance Level $45.90 $2.26
Average True Range (ATR) 0.56 0.10
MACD -0.46 0.02
Stochastic Oscillator 14.95 79.73

Price Performance

Historical Comparison
FNWD
BDTX

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: